Physician profile
Robert Schnackenberg
NPI 1548240484
$5,698.25
in general payments reported to CMS, 2019-2025
31 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $238 · 2021: $302 · 2022: $418 · 2023: $957 · 2024: $1,546 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.14 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.76 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $674.42 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $651.09 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $463.57 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Bausch Health US, LLC | $442.61 | 2022-2025 | Aplenzin |
| Lundbeck LLC | $426.25 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $404.77 | 2019-2023 | Invega Sustenna |
| Alkermes, INC. | $300.97 | 2019-2025 | Lybalvi, Aristada |
| Noven Therapeutics, LLC | $198.65 | 2024-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $158.30 | 2022-2025 | Auvelity |
| Almatica Pharma LLC | $94.08 | 2024-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $87.13 | 2023-2025 | Quviviq, Quviviq |
| Adlon Therapeutics L.P. | $83.68 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $78.73 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $69.56 | 2019-2025 | Fanapt, Hetlioz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $68.40 | 2019-2024 | Jornay Pm |
| Corium, LLC | $68.12 | 2023-2024 | Azstarys |
| Tris Pharma INC | $64.40 | 2022-2023 | Dyanavel Xr |
| Shire North American Group INC | $59.01 | 2019 | |
| Arbor Pharmaceuticals, INC. | $57.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.01 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $48.11 | 2023-2024 | Austedo Xr, Uzedy |
| Vertical Pharmaceuticals, LLC | $27.47 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.61 | 2023 | |
| Jazz Pharmaceuticals INC. | $17.39 | 2019 | |
| Allergan, INC. | $16.28 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.31 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $12.97 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.75 | 2019 | |
| Neos Therapeutics, Lp | $11.70 | 2020 | |
| Eisai INC. | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schnackenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.